Leukemia and Lymphoma

The high cost of specialty drugs continues to plague the healthcare industry. Here’s why.

Catherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.

Here’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.

A new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)

While CAR T-cell therapy has been proven to work for liquid-or blood-cancers, the challenge has been to apply this technology to solid tumors.

Transplant eligibility issues and drug regimen options raise difficult questions when treating older multiple myeloma patients.

CAR T-cell therapies and other immunotherapy give this oncologist’s cancer patients hope for a better quality of life.

Early detection of breast cancer continues to be the best way to save lives and decrease healthcare costs over time, and new technology could help.

Managing the care for members with cancer is unlike managing care for other chronic diseases. Here’s five ways to better care for cancer patients.

Experts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.

As multiple myeloma treatment improvements continue, it’s important for managed care executives to get out in front of these 10 changes on the horizon.

Unique partnerships between payers and providers focus on keeping patients out of the hospital and on the road to remission.

Just as cancer takes many forms, so does genetic testing. Here’s what you need to know.

Moffitt Cancer Center expert shares her thinking on managing chemotherapy-related side effects.

While targeted cancer therapies make up a big part of the pipeline, there are three areas that oncology experts want you to keep on your radar.

Key takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.

One study seeks to understand the underlying causes of racial and ethnic disparities in cancer survival. The results may be surprising.

As genomics continues to evolve, here are five things to know about genetic testing and counseling.

With the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.

CAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.

Acute myeloid leukemia experts share promising new developments on the oncology horizon.

Physicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.

Oncology is a complex and rapidly-evolving management challenge for payers.

Biomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.

Inherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.

In this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.

Novel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.

Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.

Researchers see promising early clinical trials with checkpoint-inhibitor therapies, opening the door for checkpoint-blockade combo therapies.

How plans can achieve the right balance between cost and outcomes